This issue focuses attention to the rise in people living with diabetes worldwide and the price we are all paying for diabetes prevention, care and treatment, directly and indirectly.
Characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. DME-related healthcare costs were determined over 6 months, and vision-related, and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Mean 6-month DME-related costs/patient were as follows: all patients (n =